The global diversion of pharmaceutical drugs: Opiate treatment and the diversion of pharmaceutical opiates: A clinician's perspective

Addiction

Volumn 105, Issue 9, 2010, Pages 1531-1537

  Bell, James ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

Buprenorphine; clinical audit; diversion; guidelines; methadone; opioids; prescription drugs

Indexed keywords

METHADONE; NARCOTIC ANALGESIC AGENT; PRESCRIPTION DRUG;

ARTICLE; AUSTRALIA; DRUG CONTROL; DRUG DEPENDENCE TREATMENT; FRANCE; HUMAN; LEGAL ASPECT; MEDICAL AUDIT; MORTALITY; OPIATE ADDICTION; ORGANIZATION AND MANAGEMENT; PATIENT ATTITUDE; PUBLIC OPINION; UNITED KINGDOM; UNITED STATES; UTILIZATION REVIEW;

ANALGESICS, OPIOID; AUSTRALIA; CLINICAL AUDIT; DRUG AND NARCOTIC CONTROL; FRANCE; GREAT BRITAIN; HUMANS; METHADONE; OPIOID-RELATED DISORDERS; PATIENT ACCEPTANCE OF HEALTH CARE; PRESCRIPTION DRUGS; PUBLIC OPINION; SUBSTANCE ABUSE TREATMENT CENTERS; UNITED STATES;

EID: 77955406807     PISSN: 09652140     EISSN: 13600443     Source Type: Journal    
DOI: 10.1111/j.1360-0443.2010.03014.x     Document Type: Article

References (41)

1. Jaffe J., O'Keeffe C. From morphine clinics to buprenorphine; regulating opioid agonist treatment of addiction in the United States. Drug Alcohol Depend 2003 70 : S3 S11.
2. Goldstein A., Hanstein R. W., Horns M. Control of methadone dosage by patients. JAMA 1975 234 : 734 737.
3. Bell J., Dru A., Fischer B., Levit S., Sarfraz M. A. Substitution therapy for heroin addiction. Subst Use Misuse 2002 37 : 1145 1174.
4. Lintzeris N., Lenne M., Ritter A. Methadone injecting in Australia: a tale of two cities. Addiction 1999 94 : 1175 1178.
5. Fountain J., Strang J., Gossop M., Farrell M., Griffiths P. Diversion of prescribed drugs by drug users in treatment: analysis of the UK market and new data from London. Addiction 2000 95 : 393 406.
6. Sunjic S., Zador D. Methadone syrup-related deaths in New South Wales, Australia, 1990-95. Drug Alcohol Review 1999 18 : 409 415.
7. Farrell M., Neeleman J., Griffiths P., Howes S., Strang J. Fatal methadone and heroin overdose in the United Kingdom: a growing problem? In : Hall W., editor. Proceedings of an International Opioid Overdose Symposium, Sydney, Australia, August 14-15, 1997, NDARC Monograph no. 35. Sydney : National Drug and Alcohol Research Centre 1998, p. 37 41.
8. Neeleman J., Farrell M. Fatal methadone and heroin overdoses; time trends in England and Wales. J Epidemiol Commun Health 1997 51 : 435 437.
9. Department of Health. The Taskforce to Review Services for Drug Misusers. Report of an independent review of drug treatment services in England. London : Department of Health 1996.
10. Department of Health. Drug Misuse and Dependence - Guidelines on Clinical Management. London : Stationary Office 1999.
11. Morgan O., Griffiths C., Hickman M. Association between availability of heroin and methadone and fatal poisoning in England and Wales 1993-2004. Int J Epidemiol 2006 35 : 1579 1585.
12. Zador D., Mayet S., Strang J. Commentary: decline in methadone-related deaths probably relates to increased supervision in UK. Int J Epidemiol 2006 35 : 1586 1587.
13. Roberts K., Hunter C. A comprehensive system of pharmaceutical care for drug misusers. Harm Reduct J 2004 1 : 1 6.
14. Bell J., Butler B., Lawrance A., Batey R., Salmelainen P. Comparing overdose mortality associated with methadone and buprenorphine treatment. Drug Alcohol Depend 2009 104 : 73 7.
15. Darke S., Ross J., Hall W. The Injection of Methadone Syrup in Sydney, Australia. Technical Report no. 23. Sydney : National Drug and Alcohol Research Centre 1995.
16. Darke S., Topp L., Ross J. The injection of methadone and benzodiazepines among Sydney injecting drug users 1996-2000: 5-year monitoring of trends from the Illicit Drug Reporting System. Drug Alcohol Rev 2002 21 : 27 32.
17. Ritter A., Di Natale R. The relationship between take-away methadone policies and methadone diversion. Drug Alcohol Rev 2005 244 : 347 352.
18. Kinner S., Fischer J. Queensland Drug Trends 2003 Findings from the Illicit Drug Reporting System (IDRS). NDARC Technical Report no. 177. Sydney : National Drug and Alcohol Research Centre 2003.
19. Centre for Substance Abuse Treatment. Methadone Associated Mortality; Report of A National Assessment. Rockville, MD : US Department of Health and Human Services, Substance Abuse and Mental Health Services Administration 2004.
20. Smith M. Y., Bailey J. E., Woody G. E., Kleber H. D. Abuse of buprenorphine in the United States - 2003-2005. J Addict Dis 2007 26 : 107 111.
21. Paulozzi L. J. Opioid analgesic involvement in drug abuse deaths in American metropolitan areas. Am J Public Health 2006 96 : 1755 1757.
22. Rosenblum A., Parrino M., Schnoll S. H., Fong C., Maxwell C., Cleland C. M. Prescription opioid abuse among enrollees into methadone maintenance treatment. Drug Alcohol Depend 2007 90 : 64 71.
23. Rhoades H. M., Creson D., Elk R., Schmitz J., Grabowski J. Retention, HIV risk, and illicit drug use during treatment: methadone dose and visit frequency. Am J Public Health 1998 88 : 34 9.
24. Vidal-Trecan G., Varescon I., Nabet N., Boissonnas A. Intravenous use of prescribed sublingual buprenorphine tablets by drug users receiving maintenance therapy in France. Drug Alcohol Depend 2003 69 : 175 181.
25. Bouchez J., Vignau J. The French experience - the pharmacist, general practitioner and patient perspective. Eur Addict Res 1998 4 : 19 23.
26. Auriacombe M., Fatséas M., Dubernet J., Daulouède J. P., Tignol J. French field experience with buprenorphine. Am J Addict 2004 13 : S17 28.
27. Cleaver H. Georgian drug misusers switch to western heroin substitute. BMJ 2007 334 : 821.
28. Chua S.-M., Lee T.-S. Abuse of prescription buprenorphine, regulatory controls and the role of the primary physician. Ann Acad Med Singapore 2006 35 : 492 495.
29. Neale J. Drug users' views of substitute prescribing conditions. Int J Drug Policy 1999 10 : 247 258.
30. Bell J., Shearer J., Ryan A., Graham R., Korompay K., Rizzo S. et al. The acceptability, safety and tolerability of methadone/naloxone in a 50:1 ratio. Exp Clin Psychopharmacol 2009 17 : 146 153.
31. Bruce R. D., Govindasamy S., Sylla L., Kamarulzaman A., Altice F. L. Lack of reduction in buprenorphine injection after introduction of co-formulated buprenorphine/ naloxone to the Malaysian market. Am J Drug Alcohol Abuse 2009 35 : 68 72.
32. Alho H., Sinclair D., Vuori E., Holopainen A. Abuse liability of buprenorphine-naloxone tablets in untreated IV drug users. Drug Alcohol Depend 2007 88 : 75 8.
33. Larance B., Degenhardt L., Mattick R., O'Brien S., Lintzeris N., Bell J. et al. The Diversion and Injection of the Pharmaceutical Opioids Used in Opioid Substitution Treatment: Findings from the Australian Post-Marketing Surveillance Studies of Buprenorphine-Naloxone, 2006-2008. Technical report. Sydney : National Drug and Alcohol Research Centre 2009.
34. Opiod drugs in maintenance and detoxification treatment of heroin addiction; final rule. Fed Regist 2001 66 : 4085 42 CFR Part 8.
35. Henry-Edwards S., Gowing L., White J., Ali R., Bell J., Brough R. et al. Clinical Guidelines and Procedures for the Use of Methadone in the Maintenance Treatment of Opioid Dependence. Canberra : Commonwealth of Australia 2003.
36. Webster L. R., Webster R. M. Predicting aberrant behaviours in opioid-treated patients: validation of the Opioid Risk Tool. Pain Med 2005 6 : 432 442.
37. Katz N. P., Sherburne S., Beach M., Rose R. J., Vielguth J., Bradley J. et al. Behavioral monitoring and urine toxicology testing in patients receiving long-term opioid therapy. Anesth Analg 2003 97 : 1097 1102.
38. Gourlay D., Heit H. A., Almahrezi A. Universal precautions in pain medicine: a rational approach to the treatment of chronic pain. Pain Med 2005 6 : 107 112.
39. Hailstone S., Indig D., Lawrance A., Gill A., Anns M. Prescription Methadone Takeaway Doses; Audit and Follow-up Intervention. Abstracts, APSAD Conference, Melbourne. Sydney : Australian Professional Society on Alcohol and Drugs 2005.
40. Strang J., Manning V., Mayet S., Ridge G., Best D., Sheridan J. Does opiate prescribing for addiction change after national guidelines? Methadone and buprenorphine prescribing to opiate addicts by general practitioners and hospital doctors in England, 1995-2005. Addiction 2007 102 : 761 770.
41. Des Jarlais D. C., Paone D., Friedman S. R., Peyser N., Newman R. G. Regulating controversial programs for unpopular people: methadone maintenance and syringe exchange programs. Am J Public Health 1995 85 : 1577 1584.